10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.622.0609

CD33 (SIGLEC3) Antibody (N-term)

Purified Rabbit Polyclonal Antibody (Pab)

Catalog # AP1622A

Specification

CD33 (SIGLEC3) Antibody (N-term) - Product Information

Application	**WB, IHC-P,E**
Primary Accession	P20138
Reactivity	**Human**
Host	**Rabbit**
Clonality	**Polyclonal**
Isotype	**Rabbit Ig**
Antigen Region	**12-39**

CD33 (SIGLEC3) Antibody (N-term) - Additional Information

Gene ID 945

Other Names
Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, gp67, CD33, CD33, SIGLEC3

Target/Specificity
This CD33 (SIGLEC3) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 12-39 amino acids from the N-terminal region of human CD33 (SIGLEC3).

Dilution
WB~~1:1000
IHC-P~~1:10~50

Format
Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Storage
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions
CD33 (SIGLEC3) Antibody (N-term) is for



The anti-Siglec3 N-term Pab (Cat. #AP1622a) is used in Western blot to detect Siglec3 in jurkat cell lysate.



Formalin-fixed and paraffin-embedded human lymph with CD33 (SIGLEC3) Antibody (N-term), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.

research use only and not for use in diagnostic or therapeutic procedures.

CD33 (SIGLEC3) Antibody (N-term) - Protein Information

Name CD33

Synonyms SIGLEC3

Function
Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state (PubMed:10611343, PubMed:15597323, PubMed:11320212). Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans (PubMed:7718872). Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK (PubMed:28325905, PubMed:10887109). These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP- 2 (PubMed:10556798, PubMed:10206955, PubMed:10887109). In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules (PubMed:10206955,

CD33 (SIGLEC3) Antibody (N-term) - Background

SIGLEC3 is a putative adhesion molecule of myelomonocytic-derived cells that mediates sialic-acid dependent binding to cells. It preferentially binds to alpha2,6-linked sialic acid; the sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface. In the immune response, SIGLEC3 may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. This protein Induces apoptosis in acute myeloid leukemia (in vitro). It has been shown to interact with PTPN6/SHP-1 and PTPN11/SHP-2 upon phosphorylation. SIGLEC3 expresses in monocytic/myeloid lineage cells, and contains 2 copies of a cytoplasmic motif that is referred to as the immunoreceptor tyrosine-based inhibitor motif (ITIM). This motif is involved in downmodulation of cellular responses. The phosphorylated ITIM motif binds to the SH2 domain of PTPN6/SHP-1. Phosphorylation of Tyr-340 is involved in binding to PTPN6 and PTPN11. Phosphorylation of Tyr-358 is involved in binding to PTPN6. The gene for SIGLEC3 belongs to the immunoglobulin superfamily.

CD33 (SIGLEC3) Antibody (N-term) - References

Strausberg, R.L., et al., Proc. Natl. Acad. Sci. U.S.A. 99(26):16899-16903 (2002).
Yousef, G.M., et al., Gene 286(2):259-270 (2002).
Vitale, C., et al., Proc. Natl. Acad. Sci. U.S.A. 98(10):5764-5769 (2001).
Taylor, V.C., et al., J. Biol. Chem. 274(17):11505-11512 (1999).
Ulyanova, T., et al., Eur. J. Immunol. 29(11):3440-3449 (1999).

PubMed:10887109). One of the repressive effect of CD33 on monocyte activation requires phosphoinositide 3-kinase/PI3K (PubMed:15597323).

Cellular Location
[Isoform CD33M]: Cell membrane; Single-pass type I membrane protein

Tissue Location
Monocytic/myeloid lineage cells. In the brain, CD33 is mainly expressed on microglial cells

CD33 (SIGLEC3) Antibody (N-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture